Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.

ABSTRACT:

Background

Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safety of favipiravir for patients with COVID-19 is limited.

Methods

We conducted a systematic review of published studies reporting the efficacy of favipiravir against COVID-19. Two investigators independently searched PubMed, the Cochrane Database of Systematic Reviews, MedRxiv, and ClinicalTrials.gov (inception to September 2020) to identify eligible studies. A meta-analysis was performed to measure viral clearance and clinical improvement as the primary outcomes.

Results

Among 11 eligible studies, 5 included a comparator group. Comparing to the comparator group, the favipiravir group exhibited significantly better viral clearance on day 7

SUBMITTER: Manabe T 

PROVIDER: S-EPMC8159019 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature